Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"

Stopped early

Conditions studied: Neoplasms, Non-hematologic - Stage I-III

In brief

The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor-derived nucleic acids in the blood of patients diagnosed with an early stage solid tumor who are either commencing, currently undergoing or have completed treatment. This approach will allow the investigators to develop a quantitative measure of therapy efficacy via the counting of the relative changes in tumor molecules over the course of treatment.

Key facts

Study ID: NCT03071809
Run by: Lexent Bio, Inc.
People needed: 5
Starts: 2017-06-30
Expected to finish: 2019-03-15
Last updated by the study team: 2019-08-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

For all participants:
Age 18 years or older
Able to understand and grant informed consent
Able to have their blood drawn at enrollment before surgery and 7 to 28 days after surgery
For participants with early stage solid tumors:
Diagnosed with an early stage (I-III) solid tumor with curative intent surgery without neoadjuvant therapy planned
For "healthy control" subgroup:
No prior or current diagnosis of any cancer. Participants with prior in situ cancer or non-melanoma skin cancer will be allowed to participate but will not be included in the "healthy control" cohort and will be analyzed separately.

You may not qualify if…

Unable to grant informed consent or comply with all study procedures
Diagnosed with a hematological malignancy (acute or chronic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myeloma or lymphoma).

Where it is running

Alisa Williams, MD Inc — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.